12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Truvada emtricitabine/tenofovir: Phase II started

NIH's National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, U.S. Phase II NEXT-PrEP trial in about 400 men who have sex with men and are not infected with HIV to evaluate once-daily oral regimens of maraviroc alone, maraviroc plus emtricitabine, maraviroc plus tenofovir disoproxil fumarate and emtricitabine plus tenofovir for 48 weeks. Subjects will be tested for HIV...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >